Arch Therapeutics, Inc. Breaking 52 Week High

Arch Therapeutics, Inc. Breaking 52 Week High

Arch Therapeutics, Inc. (OTCQB: ARTH), developer of the AC5 Surgical Hemostatic Device, has garnered some interest by retail investors as the stock broke through its 52 week high of $0.45 with above average volume. Arch announced last month they obtained favorable results from a broad panel of preclinical biocompatibility tests that were performed on AC5, which is required prior to the planned filing of a CE Mark application and commercialization of AC5 in Europe.

Related posts

Leave a Comment